Bausch + Lomb Corporation
- Open
- 16.63
- Day high
- 16.66
- Day low
- 16.32
- Prev close
- 16.63
- Volume
- 274K
- Mkt cap
- $6.0B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 0.9
- P/S
- 1.1
- Yield
- —
- Per share
- —
Bausch + Lomb Corporation (BLCO) is a Healthcare company listed on NYSE. The stock is up 23% over the past year.
Bausch + Lomb Corporation (BLCO) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
BLCO earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 29, 2026 | $0.06 | $0.08 | +33.3% | $1.2B | +2.3% |
| Feb 18, 2026 | $0.35 | $0.32 | -8.6% | $1.4B | +15.5% |
| Oct 29, 2025 | $0.16 | $0.18 | +12.5% | $1.3B | -7.4% |
| Jul 30, 2025 | $0.06 | $0.07 | +16.7% | $1.3B | +0.3% |
| Apr 30, 2025 | $0.03 | $-0.07 | -333.3% | $1.1B | -9.6% |
| Feb 19, 2025 | $0.24 | $0.25 | +4.2% | $1.3B | +11.2% |
| Oct 30, 2024 | $0.16 | $0.17 | +6.3% | $1.2B | -4.7% |
| Jul 31, 2024 | $0.13 | $0.13 | +0.0% | $1.2B | -24.3% |
| May 1, 2024 | $0.09 | $0.07 | -22.2% | $1.1B | -32.1% |
| Feb 21, 2024 | $0.17 | $0.24 | +41.2% | $1.2B | -21.7% |
| Nov 1, 2023 | $0.18 | $0.22 | +22.2% | $1.0B | -26.0% |
| Aug 2, 2023 | $0.16 | $0.18 | +12.5% | $1.0B | +7.6% |
BLCO insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 16, 2026 | Bonnefoy Lucofficer: President, Surgical | Tax | 1,008 | $15.08 |
| May 28, 2026 | Alfonso Eduardodirector | Grant | 15,842 | $15.78 |
| May 28, 2026 | Bernier Nathalie D.director | Grant | 15,842 | $15.78 |
| May 28, 2026 | VON ESCHENBACH ANDREW C.director | Grant | 15,842 | $15.78 |
| May 28, 2026 | Ross Thomas W. Sr.director | Grant | 15,842 | $15.78 |
| May 28, 2026 | ROBERTSON RUSSEL Cdirector | Grant | 15,842 | $15.78 |
| May 28, 2026 | Paulson Johndirector | Grant | 15,842 | $15.78 |
| May 28, 2026 | Ling Karendirector | Grant | 15,842 | $15.78 |
| May 28, 2026 | KAVANAGH SARAH Bdirector | Grant | 15,842 | $15.78 |
| May 28, 2026 | COLLIS STEVEN Hdirector | Grant | 15,842 | $15.78 |
| May 26, 2026 | SAUNDERS BRENT Ldirector, officer: Chairman of the Board and CEO | Tax | 2,886 | $15.92 |
| May 7, 2026 | Munsch Frederickofficer: SVP, Controller and CAO | Tax | 8,673 | $16.00 |
| May 7, 2026 | Bonnefoy Lucofficer: President, Surgical | Tax | 11,970 | $16.00 |
| May 7, 2026 | Hashad Yehiaofficer: EVP of R&D and CMO | Tax | 13,664 | $16.00 |
| May 7, 2026 | Eldessouky Samofficer: EVP and CFO | Tax | 63,938 | $16.00 |
Source: BLCO SEC Form 4 filings, latest Jun 16, 2026. For informational purposes only — not investment advice.
See the full BLCO insider & 13F page →Bausch + Lomb Corporation company profile
Overview
Bausch + Lomb Corporation (NYSE:BLCO) is a global eye health company with roots dating back to 1853, making it one of the oldest and most established names in vision care. Originally founded as an optical goods company in Rochester, New York, Bausch + Lomb has evolved into a comprehensive eye health enterprise. The company went public in May 2022 following a spinoff from Bausch Health Companies, establishing itself as an independent publicly traded entity focused exclusively on eye care products and services. Today, the company operates from its headquarters in Vaughan, Canada, and serves customers worldwide across three distinct business segments covering the entire spectrum of eye health needs.
Business
Bausch + Lomb operates as a comprehensive eye health company serving both consumers and healthcare professionals through three primary business segments. The Vision Care/Consumer Health Care segment represents the largest portion of the business, generating approximately 57% of total revenue ($2.7 billion in 2024). This division manufactures and distributes contact lenses across all wearing modalities, from daily disposable lenses to frequently replaced options, including their fast-growing Daily SiHy (silicone hydrogel) product line. The segment also produces contact lens care solutions, over-the-counter eye drops like LUMIFY for red eye relief, and nutritional supplements such as PreserVision and Ocuvite eye vitamins that support overall eye health. The Ophthalmic Pharmaceuticals segment accounts for roughly 25% of revenue ($1.2 billion in 2024) and focuses on prescription medications for various eye conditions. This includes treatments for glaucoma, ocular hypertension, and retinal diseases, as well as post-operative care products. Key products include MIEBO for dry eye disease, XIIDRA (also for dry eye), and VYZULTA for glaucoma treatment. The segment serves both branded and generic pharmaceutical markets. The Surgical segment represents approximately 18% of revenue ($843 million in 2024) and provides surgical tools, technologies, and devices primarily for cataract and retinal surgeries. This includes intraocular lenses (IOLs) that replace the eye's natural lens during cataract surgery, phacoemulsification equipment used to break up cataracts, and various surgical instruments. The segment offers both standard and premium IOL options, with premium products commanding higher margins and showing strong growth.
Revenue model
Bausch + Lomb generates revenue through multiple channels depending on the business segment. The Vision Care division operates primarily through product sales to retailers, distributors, and eye care professionals, selling contact lenses, lens care solutions, and over-the-counter eye health products directly to consumers and through professional channels. The company also operates digital platforms like Opal, an e-commerce marketplace for contact lenses, enabling direct-to-consumer sales. The Pharmaceuticals segment generates revenue through prescription drug sales to healthcare providers, pharmacies, and patients, with pricing influenced by insurance coverage and managed care contracts. Products like MIEBO and XIIDRA require ongoing investment in direct-to-consumer marketing campaigns to drive patient awareness and prescription demand. The Surgical segment follows a business-to-business model, selling equipment, instruments, and consumables directly to hospitals, ambulatory surgery centers, and ophthalmologists. This segment benefits from recurring revenue streams through consumable products and service contracts, while equipment sales provide larger but less frequent revenue contributions. Several factors influence the company's margins and profitability. Positive margin drivers include the shift toward premium products like Daily SiHy contact lenses and premium IOLs, which command higher prices and margins. The company's global manufacturing scale and operational excellence initiatives also support margin expansion. However, margin pressures come from competitive pricing in mature markets, supply chain disruptions, raw material cost inflation, and regulatory compliance costs. Additionally, the company faces potential tariff impacts on products manufactured outside the United States, which management estimates could affect EBITDA margins by approximately 120 basis points.
Competitive moat
Bausch + Lomb's competitive position is built on several defensive characteristics, though the strength of its moat varies across business segments. The company benefits from its long-established brand recognition and trust in the eye care market, particularly valuable in healthcare where brand reputation directly impacts physician and patient confidence. The company's comprehensive product portfolio across the entire eye care spectrum creates cross-selling opportunities and makes it a preferred partner for eye care professionals seeking one-stop solutions. The pharmaceutical segment enjoys the strongest moat through patent protection on key products like MIEBO, regulatory barriers that limit competition, and the specialized nature of ophthalmic drug development which requires significant expertise and investment. The surgical segment benefits from switching costs, as surgeons become proficient with specific equipment and are reluctant to change systems, plus the critical nature of surgical outcomes creates preference for established, trusted brands. However, the contact lens business faces more intense competition from large players like Johnson & Johnson, CooperVision, and Alcon, with fewer barriers to entry for new products. The company's moat is challenged by the commoditization of standard contact lenses and the need for continuous innovation to maintain market share. Generic competition in pharmaceuticals also poses ongoing threats as patents expire. While Bausch + Lomb has strong market positions, the eye care industry's competitive dynamics require constant investment in research and development, marketing, and operational efficiency to maintain competitive advantages.
Risks & safety
The company presents moderate financial risk with mixed safety indicators. Overall assessment shows manageable debt levels but concerning cash flow dynamics requiring attention. • **Cash and Liquidity**: $202 million cash with $968 million net current assets, providing reasonable short-term liquidity buffer • **Debt Position**: Debt-to-equity ratio of 0.76 indicates moderate leverage; total liabilities of $7.0 billion against $13.4 billion total assets • **Cash Flow Concerns**: Negative free cash flow of -$135 million in Q1 2025, negative operating cash flow of -$25 million signals operational challenges • **Solvency Risk**: Current ratio of 1.56 provides adequate coverage of short-term obligations, but declining cash position warrants monitoring • **Valuation Metrics**: Trading at 0.80x book value suggests potential undervaluation, though negative earnings make P/E ratios less meaningful • **Other Considerations**: Recent product recalls (enVista IOL) and tariff exposure create additional operational risks; company guidance suggests return to positive cash flow expected
Recent development
Over the past several years, Bausch + Lomb has executed a strategic transformation focused on accelerating growth through innovation and market expansion. The company completed its independence through a 2022 IPO, establishing itself as a pure-play eye health company under new leadership with Brent Saunders as CEO. Key strategic developments include aggressive expansion in the dry eye treatment market through the acquisition and launch of XIIDRA and the development of MIEBO, building a dry eye portfolio approaching $1 billion in annual revenue. The company has invested heavily in next-generation contact lens technology, particularly Daily SiHy lenses which have shown exceptional growth of 42-79% year-over-year, and is developing innovative biomimetic contact lenses and myopia control solutions. Digital transformation initiatives have been central to recent strategy, including the launch of Opal, an e-commerce marketplace for contact lenses, and Glimpse, an AI-driven sales platform. The company has also invested in direct-to-consumer marketing campaigns for pharmaceutical products to drive patient awareness and prescription demand. Manufacturing and operational excellence programs have focused on supply chain optimization, with new production lines installed in Milan and Berlin, and deployment of AI technology in contact lens manufacturing to improve yields. The company has also strengthened its surgical portfolio through premium IOL launches including enVista Envy trifocal lenses and is preparing for the approval of ELIOS MIGS glaucoma products. Recent challenges include managing a voluntary recall of enVista intraocular lenses due to potential complications, though the company successfully returned to market within a month through collaboration with leading surgeons.
BLCO company profile · for informational purposes only — not investment advice.
Track BLCO with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free